Humulin 70-30 (Insulin NPh Hum/Reg Insulin Hm) Patent Expiration, LOE Window & CMS Spending

Humulin 70-30 (Insulin NPh Hum/Reg Insulin Hm) by Eli Lilly: Off-Patent Genericized (AB Competition), 0 AB generics, $41.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$41.8M
2024 Medicare Part D Spend$32.2M
2024 Medicaid Spend$9.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.